Gapping up
In reaction to earnings/guidance:
- CTLT +2.8%
M&A news:
- AIMT +170.7% (to be acquired by unit of Nestlé Health Science (NSRGY) for 34.50 per share)
Other news:
- AKCA +59.1% (presents Phase 2 clinical data of AKCEA-APOCIII-L)
- CRMD +13.7% (FDA has accepted its NDA for Defencath for the prevention of catheter related blood stream infections; PDUFA goal date of February 28, 2021)
- GME +11.3% (indicated higher after RC Ventures disclosed 9% active stake)
- NGM +8.3% (presents comprehensive findings from 24-Week Phase 2 study (Cohort 4) of Aldafermin)
- BCRX +5.5% (granted Orphan Drug designation for its oral Factor D inhibitor, BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria)
- AMRN +5.3% (reports results of the EVAPORATE Trial met primary endpoint)
- DISH +5.1% (WSJ report that AT&T is in early talks to explore a deal for its DirecTV business)
- KOPN +4.6% (announced that its BDM WVGA LCD module and A912 Driver IC have been chosen by Medisim Ltd. for its BinoVision goggles)
- AXSM +3.4% (confirms pivotal status and advancement of AXS-05 for the treatment of Alzheimer's disease agitation based on successful FDA Breakthrough Therapy meeting )
- ARWR +2.5% (presents new phase 1/2 clinical data on cardiometabolic candidates ARO-APOC3 and ARO-ANG3)
- AWK +1.5% (American Water Works' Iowa American Water unit files request to adjust its rate)
- BLUE +1.4% (reports new results from clinical development program of elivaldogene autotemcel Gene Therapy for Cerebral Adrenoleukodystrophy)
- SAVE +1.4% (provides investor update; continues to experience significant adverse impact of the material decline in air travel demand due to the COVID-19 pandemic)
- T +1.1% (in early talks to explore a deal for its DirecTV business, with potential bidders said to include Apollo Global Management (APO), according to WSJ)
- HUN +1.1% (to sell its remaining interest in Venator Materials)
- TSLA +0.9% (following stock split)
- AAPL +0.8% (following stock split)
Analyst comments:
- RXT +5.5% (initiated with a Buy at Goldman; initiated with an Overweight at Barclays, among others)
- SPCE +4.2% (initiated with an Outperform at Cowen)
- OSH +3.5% (initiated with a Buy at Goldman)
- BYND +2.5% (upgraded to Neutral from Sell at Citigroup)